Kura Oncology (NASDAQ:KURA) Rating Lowered to Hold at StockNews.com

Kura Oncology (NASDAQ:KURA - Get Free Report) was downgraded by equities research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued on Tuesday.

Other equities research analysts have also issued reports about the stock. BTIG Research lowered shares of Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. Bank of America reduced their target price on shares of Kura Oncology from $36.00 to $29.00 and set a "buy" rating on the stock in a report on Friday, November 22nd. UBS Group reduced their target price on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Cantor Fitzgerald raised shares of Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Kura Oncology in a research report on Thursday, February 27th. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $25.50.

Kura Oncology Price Performance

Shares of Kura Oncology stock traded down $0.01 during midday trading on Tuesday, hitting $7.84. 2,172,610 shares of the company traded hands, compared to its average volume of 1,061,122. The stock has a market cap of $633.12 million, a price-to-earnings ratio of -3.32 and a beta of 0.85. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm's fifty day moving average price is $7.82 and its 200-day moving average price is $12.43. Kura Oncology has a 12 month low of $6.79 and a 12 month high of $23.48.

Remove Ads

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. As a group, sell-side analysts forecast that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Activity at Kura Oncology

In other news, insider Mollie Leoni sold 4,963 shares of the firm's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the company's stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares of the company's stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock valued at $92,307 in the last three months. Corporate insiders own 5.50% of the company's stock.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently bought and sold shares of KURA. Suvretta Capital Management LLC raised its holdings in shares of Kura Oncology by 8.2% in the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company's stock valued at $149,535,000 after purchasing an additional 583,155 shares during the last quarter. Vanguard Group Inc. grew its position in Kura Oncology by 14.6% in the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company's stock worth $41,973,000 after purchasing an additional 615,211 shares in the last quarter. RA Capital Management L.P. purchased a new stake in Kura Oncology in the 4th quarter valued at about $38,769,000. Millennium Management LLC lifted its position in shares of Kura Oncology by 180.1% during the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock worth $20,618,000 after buying an additional 1,521,954 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Kura Oncology by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock worth $34,798,000 after buying an additional 41,535 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.